These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15543773)

  • 1. [Critical appraisal: Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Prandoni P, Carnovali M, Marchiori A, Galilei investigators. Arch Intern Med 2004; 164: 1077-83].
    Burotto M; Gabrielli L; Crossley N
    Rev Med Chil; 2004 Sep; 132(9):1140-3. PubMed ID: 15543773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
    Prandoni P; Carnovali M; Marchiori A;
    Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.
    ; Büller HR; Gent M; Gallus AS; Ginsberg J; Prins MH; Baildon R
    N Engl J Med; 1997 Sep; 337(10):657-62. PubMed ID: 9280815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
    Riess H; Koppenhagen K; Tolle A; Kemkes-Matthes B; Gräve M; Patek F; Drexler M; Siemens HJ; Harenberg J; Weidinger G; Brom J; Haas S;
    Thromb Haemost; 2003 Aug; 90(2):252-9. PubMed ID: 12888872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.
    Kearon C; Ginsberg JS; Julian JA; Douketis J; Solymoss S; Ockelford P; Jackson S; Turpie AG; MacKinnon B; Hirsh J; Gent M;
    JAMA; 2006 Aug; 296(8):935-42. PubMed ID: 16926353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight heparin versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism.
    Findik S; Erkan ML; Selçuk MB; Albayrak S; Atici AG; Doru F
    Respiration; 2002; 69(5):440-4. PubMed ID: 12232452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
    van Dongen CJ; van den Belt AG; Prins MH; Lensing AW
    Cochrane Database Syst Rev; 2004 Oct; (4):CD001100. PubMed ID: 15495007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group.
    Koopman MM; Prandoni P; Piovella F; Ockelford PA; Brandjes DP; van der Meer J; Gallus AS; Simonneau G; Chesterman CH; Prins MH
    N Engl J Med; 1996 Mar; 334(11):682-7. PubMed ID: 8594426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous unfractionated heparin for the treatment of venous thromboembolism.
    Kearon C
    Curr Opin Pulm Med; 2007 Sep; 13(5):398-402. PubMed ID: 17940484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial.
    Massicotte P; Julian JA; Gent M; Shields K; Marzinotto V; Szechtman B; Andrew M;
    Thromb Res; 2003 Jan; 109(2-3):85-92. PubMed ID: 12706636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
    Grau E; Tenias JM; Real E; Medrano J; Ferrer R; Pastor E; Selfa S
    Am J Hematol; 2001 May; 67(1):10-4. PubMed ID: 11279651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.
    van Den Belt AG; Prins MH; Lensing AW; Castro AA; Clark OA; Atallah AN; Burihan E
    Cochrane Database Syst Rev; 2000; (2):CD001100. PubMed ID: 10796593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of nadroparin and unfractionated heparin for the treatment of venous thromboembolism during pregnancy and puerperium.
    Mitić G; Kovac M; Povazan L; Djordjević V; Ilić V; Salatić I; Lazić R; Antonijević N; Novakov-Mikić A
    Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():18-22. PubMed ID: 20229677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials.
    Quinlan DJ; McQuillan A; Eikelboom JW
    Ann Intern Med; 2004 Feb; 140(3):175-83. PubMed ID: 14757615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire.
    Simonneau G; Sors H; Charbonnier B; Page Y; Laaban JP; Azarian R; Laurent M; Hirsch JL; Ferrari E; Bosson JL; Mottier D; Beau B
    N Engl J Med; 1997 Sep; 337(10):663-9. PubMed ID: 9278462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy.
    Douketis JD; Foster GA; Crowther MA; Prins MH; Ginsberg JS
    Arch Intern Med; 2000 Dec 11-25; 160(22):3431-6. PubMed ID: 11112236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times.
    Anand SS; Bates S; Ginsberg JS; Levine M; Buller H; Prins M; Haley S; Kearon C; Hirsh J; Gent M
    Arch Intern Med; 1999 Sep; 159(17):2029-32. PubMed ID: 10510988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.